Alzheimer's Prevention Registry Reaches Recruitment Milestone of 40,000 Individuals - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Alzheimer's Prevention Registry Reaches Recruitment Milestone of 40,000 Individuals Online community helping to accelerate critical Alzheimer's research


Alzheimer's Prevention Registry Reaches Recruitment Milestone of 40,000 Individuals

Online community helping to accelerate critical Alzheimer's research

PR Newswire

PHOENIX, Aug. 25, 2014 /PRNewswire/ -- The Alzheimer's Prevention Registry today reached a significant milestone in the fight against Alzheimer's by enrolling the 40,000th volunteer interested in participating in major studies of the disease. Championed by Banner Alzheimer's Institute (BAI) and in collaboration with partnering organizations and leading scientists, the online Registry (www.endALZnow.org) aims to accelerate research by connecting healthy individuals who are committed to preventing Alzheimer's with scientists carrying out the studies.

"Every person who joins is helping to further research and is bringing us one step closer to unlocking the mysteries of this devastating disease," said Jessica Langbaum, Ph.D., principal scientist at BAI and associate director of the Alzheimer's Prevention Initiative (API). "We're excited about the momentum of current prevention research, as many studies begin to recruit and the Registry plays a crucial role in overcoming recruitment barriers."

The Registry is unique in that anyone 18 or older with a passion for combating Alzheimer's can be linked to researchers seeking a cure or a new treatment. It was created as part of the API, an international collaborative launched in 2011 to accelerate the pace of research.

Alzheimer's begins developing in the brain long before any symptoms appear - a critical "silent" period during which scientists believe the disease could be slowed or even stopped. But researchers say that cutting-edge research can be delayed, sometimes by years, because of the difficulty of finding sufficient numbers of volunteers.  Clinical trials sometimes need to screen tens of thousands of individuals in order to find the hundreds of participants who fit the trial criteria.

As Alzheimer's remains the only disease among the top 10 causes of death that has no cure or treatment, the Registry is urgently pushing to accelerate the pace of much-needed research by recruitment both in the U.S. and internationally. Registry members also receive regular updates on the latest scientific advances, and news and information on overall brain health, Langbaum said.

Alzheimer's is a debilitating and incurable disease that affects as many as five million Americans age 65 and older. Without the discovery of successful prevention therapies, the number of U.S. cases is projected to nearly triple by 2050.

For more information, or to sign up, visit the Registry at www.endALZnow.org .

SOURCE Banner Alzheimer's Institute

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document

Click here